Compare Adaptive Biotechnologies Corp (ADPT) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Costco Wholesale Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.01 (market cap $4.04B), while Costco Wholesale Corporation trades at $947.96 (market cap $418.79B). The key difference: Costco Wholesale Corporation is far larger — about 103.7× Adaptive Biotechnologies Corp's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | COST | |
|---|---|---|
Market Cap | $4.04B | $418.79B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $1.09K |
52-Week Low | $12.30 | $849.63 |
Enterprise Value | $4.10B | $406.93B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
COST trades at $952.75, up 0.52% today, with a neutral technical signal. The stock shows strong fundamentals, including revenue growth to $275.24B in 2025 and consistent earnings beats, though Q1 2026 missed estimates. Positive sentiment is driven by a 65.52% analyst buy rating and a consensus price target of $1,120. Recent news highlights membership fee hikes and robust March sales, supporting investor confidence.
Outlook remains favorable due to steady growth and high institutional ownership, but risks include elevated valuation (P/E 47.5) and competitive pressures. The stock offers long-term potential if earnings momentum continues, though near-term volatility may persist amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
